Re: IL-15 Superagonist NAI in BCG-Unresponsive Non–muscle-invasive Bladder Cancer
- 1 June 2023
- journal article
- editorial
- Published by Elsevier BV in European Urology
- Vol. 83 (6), 581
- https://doi.org/10.1016/j.eururo.2023.01.009
Abstract
No abstract availableThis publication has 3 references indexed in Scilit:
- Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 studyThe Lancet Oncology, 2021
- Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trialThe Lancet Oncology, 2020
- Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder CancerJournal of Urology, 2020